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Abstract
Background:  In the eye, melatonin plays a role in promoting light sensitivity at night and
modulating many aspects of circadian retinal physiology. It is also an inhibitor of retinal dopamine,
which is a promoter of day vision through the cone system. Consequently, it is possible that oral
melatonin (an inhibitor of retinal dopamine) taken to alleviate circadian disorders may affect cone
functioning. Our aim was to assess the impact of melatonin on the cone response of the human
retina using electroretinography (ERG).
Methods: Twelve healthy participants aged between 18 to 52 years old were submitted to a
placebo-controlled, double-blind, crossover, and counterbalanced-order design. The subjects were
tested on 2 sessions beginning first with a baseline ERG, followed by the administration of the
placebo or melatonin condition and then, 30 min later, a second ERG to test the effect.
Results: Following oral melatonin administration, a significant decrease of about 8% of the cone
maximal response was observed (mean 6.9 μV ± SEM 2.0; P = 0.0065) along with a prolonged b-
wave implicit time of 0.4 ms ± 0.1, 50 minutes after ingestion.
Conclusion:  Oral melatonin appears to reach the eye through the circulation. When it is
administered at a time of day when it is not usually present, melatonin appears to reduce input to
retinal cones. We believe that the impact of melatonin on retinal function should be taken into
consideration when used without supervision in chronic self-medication for sleep or circadian
disorder treatment.
Background
Melatonin is a circulating hormone (N-acetyl-5 methox-
ytryptamine) produced mostly by the pineal gland at
night [1]. Considering that melatonin feeds back to the
suprachiasmatic nucleus (SCN), site of the internal clock,
where melatonin receptors are also located [2], it is sug-
gested that melatonin may be a regulatory hormone of
darkness for the SCN. Of interest, melatonin can also be
suppressed by light exposure to the eyes not only in ani-
mals but also in humans [3]. Because the production of
this hormone is "light sensitive", it is not surprising that it
is also produced in the retina by the photoreceptors [4]
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and that melatonin MT1 receptors have been localized in
the mammalian eye including the human eye [5]. In fact,
melatonin is produced by many structures of the eye
including the lens [6], the iris, the ciliary body [7] and the
lacrimal glands [8]. Moreover, there is strong evidence for
the existence of an ocular circadian clock in mammals.
This implies the possibility of interactions between retinal
processes and the SCN, which could represent an impor-
tant input in the control of circadian rhythms [9]. For
example, it was found that the mouse retina possesses its
own circadian clock and that it regulates the circadian pat-
tern of melatonin secretion [10] albeit the latter appears
to be also under partial control of the pineal gland [11].
Retinal melatonin appears to play a role in promoting
light sensitivity at night and modulating many aspects of
circadian retinal physiology such as rod disk shedding
[12,13]. Beside melatonin, it has been shown in avian ret-
ina that dopamine is produced from specific amacrine
cells [14] and in a circadian rhythm manner in the rat ret-
ina [15]. In various animal models, while melatonin pro-
duction is known to increase during the night, dopamine
production, triggered by light, is produced mostly during
the day [16]. In rodents, these two retinal neuromediators
appear to act as mutually inhibitory signals [17,18], so
that when melatonin level is high dopamine level is low
and when dopamine level is high melatonin level is low.
Consequently, melatonin is thought to promote night
vision (rod pathway)[19] whereas dopamine appears to
promote day vision (cone pathway) [16].
Due to the close link between melatonin and the biologi-
cal clock, studies have been performed to use it as a possi-
ble resynchronizing agent to treat jetlag [20] and sleep
disorders with doses ranging from as low as 0.03 mg to as
high as 85 mg [21]. Toxicity of melatonin administration
on retinal health may, however, represent a concern since
this hormone seems to impact the susceptibility to light-
induced damage of rat's photoreceptors [22,23]. It could
also disturb retinal functioning by interfering with normal
dopamine levels necessary to enhance day vision. In fact,
a study by Emser and colleagues [24] showed that oral
administration of 10 mg of melatonin induces a cone
response ERG decline in human. Because the latter study
used only a single intensity and only a red flash to test
cone function, we were interested in investigating the
impact of melatonin on the ERG dynamics of the cone
response over a wider range of intensities using conven-
tional white light flashes that allows the production of a
luminance response function from which retinal sensitiv-
ity can be determined.
Methods
Sample
The study was performed between January-February 2004
in Novosibirsk, Russia, in twelve participants (6 men and
6 women) aged between 18-52 years (mean ± SEM: 33.4
± 4.0 y). All participants were in good general health, non
smokers, with normal sleep habits and no transmeridian
travel during the last two months. The study was approved
by the Ethics Committee of the Institute of Internal Med-
icine SB RAMS. The participants were fully informed of
the nature of the study, and informed consent was
obtained.
Design
The study was composed of a placebo-controlled, double-
blind, crossover, and counterbalanced-order design. The
subjects were tested on 2 sessions separated by 2-7 days
(median = 5 days). Each session lasted two hours begin-
ning with a baseline electroretinography (ERG) followed
by one of the two treatments (placebo or melatonin) then
a second ERG. Half of the subjects began with the placebo
whereas half began with 15 mg of melatonin (Natrol®
Chatsworth, CA). On the second sessions, the baseline
was repeated followed by the other treatment. All sessions
were performed between 12:30 and 16:30.
Recording procedure
Upon their arrival at the laboratory, subjects were dilated
with 0.5% Tropicamide to ensure maximal pupil dilation
and kept in room light (~100 lux) for at least 30 minutes
before the baseline ERG recording. During this time Grass
gold disk electrodes filled with Grass EC2 electrode cream
were installed on the forehead (ground), external canthi
(reference for each eye). Active eye electrodes were DTL
fibers (Shieldex 33/9 Thread, Statex, Bremen, Germany)
placed deep into the conjunctival bag as previously
described [25].
The baseline ERG recording always started between 13:00-
15:00 and began with a 20-min light adaptation period
during which the subject was exposed to a rod saturating
white light background of 32 cd.s.m-2(~105 lux) delivered
by a ganzfeld (Color Dome; Espion system, DIAGNOSYS
LLC, Littleton, MA) in order to achieve full field stimula-
tion. During that period, 10 bright flashes [intensity: 0.84
log cd.s.m-2] delivered at 1 hertz (Hz) were presented every
5 minutes to monitor light adaptation. After the 20th min-
utes of the light adaptation period, series of 10-20 flashes
(1 Hz frequency) were presented at 7 decreasing intensi-
ties ranging from 0.39 log cd.s.m-2 to -1.45 log cd.s.m-
2(Table 1). Immediately after the end of the ERG protocol,
subject took five melatonin (total of 15 mg) or placebo
pills, and the same ERG protocol was repeated 30 min
later. During this 30-min period, the subject was kept in
room light (about 100 lux).
The white light flashes (10 μsec in duration) were gener-
ated by a tungsten stroboscope driven by a PS22 stimula-
tor (®Grass, Quincy, USA). The flash-evoked bio-potentialJournal of Circadian Rhythms 2009, 7:14 http://www.jcircadianrhythms.com/content/7/1/14
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of the retina was recorded with a band pass of 1-1000 Hz,
with an amplification of × 10 000 times (BIOPAC ampli-
fiers) and averaged on-line by means of AcqKnowledge
3.7.2 software (RC Electronic Inc., USA).
Analysis
The typical cone ERG waveform is composed of a negative
component called the a-wave followed by a positive com-
ponent called the b-wave [26]. By convention, the a-wave
implicit time is measured from the stimulus onset to the
minimum voltage (trough) of the waveform deflection
whereas the b-wave implicit time is measured from the
stimulus onset to the maximum voltage (peak) of the
waveform inflexion. The a-wave amplitude was measured
from baseline to trough, and the b-wave from the trough
of the a-wave to the peak of the b-wave. Each b-wave
amplitude were then plotted against flash intensities in
order to generate the luminance response function from
which log K parameter was derived [25]. Vmax represents
the ERG maximum b-wave amplitude observed on the
data points used to generate the luminance response func-
tion whereas log K parameter, which is interpreted as ret-
inal sensitivity, represents the flash intensity necessary to
achieve half of Vmax amplitude. Finally, oscillatory
potentials (OPs; wavelets observed on the ascending
branch of the b-wave) were extracted from the maximal
ERG response (Vmax) by bandpassing off-line the wave-
forms between 100-500 Hz. Artifact-free responses (e.g
blinks) from the two eyes were averaged prior to analysis.
Analysis of variance for repeated measures (rANOVA) was
used to assess the effect of Treatment (melatonin vs. pla-
cebo) and Time (before vs. after) on the following ERG
parameters: Vmax, a-wave and b-wave amplitude and
implicit time, log K and sum of OPs. When the rANOVA
yielded a positive result (Huynh-Feldt's corrected P <
0.05), the significant differences were analysed with Stu-
dent's paired t-test. Mean values are accompanied with the
standard errors of the means (± SEM).
Results
Figure 1 shows an example of waveforms obtained before
and after melatonin administration during adaptation
and testing period at every intensity. In Figure 2, the mean
ERG b-wave amplitudes obtained from our protocol are
plotted against intensities. It can be seen that data before
and after the placebo appear identical, whereas data
before and after melatonin appear different for: 1) both
the single intensity recorded during the light adaptation
period and 2) for the first three highest intensities of the
Table 1: Routine ERG protocol
Period Time since start, min Flash
intensity,
log cd·s·m-2
N of flashes Interval, sec. Ganzfeld background, cd·s·m-2
Adaptation 0 0.84 10 1 32
50 . 8 4 1 0 1 3 2
10 0.84 10 1 32
15 0.84 10 1 32
20* 0.84 10 1 32
Testing 0.39 10 1 32
0.10 10 1 32
-0.21 10 1 32
-0.61 10 1 32
-0.90 10 1 32
-1.10 10-20 1 32
-1.45 10-20 1 32
* The response obtained at the 20th minute represents the end of the light adaptation and the beginning of the testing periodJournal of Circadian Rhythms 2009, 7:14 http://www.jcircadianrhythms.com/content/7/1/14
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luminance response function. For the adaptation period,
rANOVA revealed a significant Treatment by Time interac-
tion for b-wave amplitude (F1,11 = 14, P = 0.0032), b-wave
implicit time (F1,11 = 7.1, P = 0.022) and a-wave implicit
time (F1,11 = 6.8, P = 0.025). Post-hoc at times 0, 5, 10 and
15 minutes after the beginning of the light adaptation
period are presented at Table 2. The b-wave amplitude was
significantly decreased after melatonin administration at
T0 (7.9 μV ± 1.9 μV), T10 (7.7 μV ± 1.8 μV) and T15 (8.5
μV ± 2.2 μV). This corresponds to a decrease of 10%, 9%
and 10% respectively. Also, a significant increase in the b-
wave implicit time after melatonin ingestion was found at
T10 only (0.4 ms ± 0.2 ms). A-wave implicit time was also
significantly longer at T0 and T10. No significant result
was found after placebo administration at any adaptation
times, for any parameter.
For the luminance response function beginning at T20 of
the light adaptation period (see Figure 2), rANOVA
revealed a significant Treatment by Time Interaction for b-
wave amplitude at intensity 0.84 log cd·s·m-2(F1,11 =
5.2, P = 0.043), 0.39 log cd·s·m-2(F1,11 = 12.4, P =
0.0048) and 0.1 log cd·s·m-2 (F1,11 = 22.4, P = 0.0006).
Student post-hoc tests are presented at Table 2, revealed
that melatonin administration diminished the amplitude
by 6.2% (5.2 μV ± 1.7 μV), 7.5% (6.3 μV ± 2.1 μV) and
9.6% (5.8 μV ± 1.3 μV) at 0.84, 0.39 and 0.1 log cd·s·m-
2, respectively. Moreover, a significant Treatment by Time
interaction was found for the b-wave implicit time (F1,11
= 13.9, P = 0.0033) at 0.84 log cd·s·m-2 for which mela-
tonin caused an increased of 0.4 ms ± 0.1 (P = 0.0061).
The only significant result for a-wave was a Treatment by
Time interaction for the a-wave implicit time at 0.84 log
cd·s·m-2 for which melatonin generated an increase of
0.1 ms ± 0.3. No significant result was found after placebo
administration at any flash intensity or any parameter.
Because the highest b-wave amplitude did not occur in all
subjects at the highest flash intensity (it was observed at
0.39 log cd·s·m-2 in 5 subjects) a separate analysis was
performed for the maximal ERG response (Vmax). Signif-
icant results were found on the Vmax b-wave amplitude
and OP's but not on a-wave or log K parameters. rANOVA
revealed a significant Treatment by Time interaction for b-
wave amplitude (F1,11 = 12.9, P = 0.0043) and implicit
time (F1,11 = 20.1, P = 0.0009). Melatonin administration
caused a significant (see Table 2) decrease of the Vmax
amplitude) of 7.9% (6.9 μV ± 2.0 μV) along with an
increase of 0.4 ms ± 0.1 ms of the implicit time. The
amplitude and implicit time of the three major waves
were analyzed: OP2, OP3, and OP4. In some cases (5 par-
ticipants), only two OPs were detected (OP2 and OP4).
However, all the subjects maintained the same number of
OPs throughout the study between conditions. Because
not all participants demonstrated 3 OPs, we opted to use
the sum of OPs for analysis. A significant interaction for
Treatment by Time was observed for the Vmax sum of OPs
amplitude (F1,11 = 5.51, p = 0.039). This amplitude was
reduced after melatonin administration by 6.97 μV ± 2.59
μV (P = 0.023), that is a decrease of 9.9%. The ratio
between the Vmax sum of OPs and the respective b-wave
amplitude was similar between conditions (F1,11 = 0.40, P
Raw ERG waveforms obtained from a male (18 y.o) before  (A) and after (B) melatonin administration during adaptation  and testing period Figure 1
Raw ERG waveforms obtained from a male (18 y.o) 
before (A) and after (B) melatonin administration 
during adaptation and testing period.Journal of Circadian Rhythms 2009, 7:14 http://www.jcircadianrhythms.com/content/7/1/14
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> 0.5). At Vmax, no significant result was found after pla-
cebo administration.
Discussion
To our knowledge, this is the first study to assess the
impact of exogenous melatonin on the human photopic
luminance response function. We observed that oral
melatonin administration induces a significant decrease
of the maximal cone response as well as a decrease of the
sum of OPs. The impact of melatonin on retinal function
was quite rapid, as it could readily be observed after 30
minutes and persisted for 50 min post ingestion. The
decrease in b-wave and sum of OPs were similar in mag-
nitude, with 6.2% to 10% for the b-wave and 9.9% for the
sum of OPs. There was no change in cone sensitivity (K
index).
The fact that we observed retinal changes in the present
study suggests that oral melatonin administration can
reach the eye through the general circulation. This is con-
sistent with a previous study using the ERG technique
showing that muscular injection of melatonin could have
even more impact on fowl's retinal response (reaching the
eye through the circulation) than intraocular injection
[27].
Because melatonin was administered at a time of day
when it is not usually present, we were able to measure its
direct impact on cone functioning without any influence
of the normal circadian secretion of melatonin in the eye,
which occurs at night. Our results are consistent with
those of previous studies. For instance, a study performed
on the green iguana demonstrated that administration of
melatonin during the subjective day reduces the cone b-
wave amplitude in a dose-response manner [28]. In
humans, an experiment performed by Rufiange et al. [29]
showed a strong correlation between the level of salivary
melatonin and the ERG cone maximal response, with cir-
cadian change in melatonin levels yielding a cone ERG
response reduction in the range of 3% to 16%. Also,
Emser et al. [19] reported similar results with a decrease of
both the scotopic and the photopic human b-wave using
10 mg of exogenous melatonin. However, in the latter
study, the scotopic ERG response was triggered by a bright
red LED flash, which likely triggered a mixed cone-rod
response. In fact, close inspection of the waveforms pre-
sented in the paper by the authors show that photopic and
scotopic responses were similar both in shape and ampli-
tude. There is therefore a strong suspicion that the find-
Changes of the amplitude of ERG response after placebo and  melatonin in 12 healthy subjects Figure 2
Changes of the amplitude of ERG response after pla-
cebo and melatonin in 12 healthy subjects. *indicates 
significant difference (P < 0.05, Student's paired t-test).
Table 2: An immediate change of the ERG indices after melatonin intake
period b-wave
amplitude
b-wave IT a-wave IT
Adaptation period T0 P = 0.0014 NS P = 0.046
T5 NS NS NS
T10 P = 0.0014 P = 0.028 P = 0.042
T15 P = 0.003 NS NS
Testing period 0.84 P = 0.011 P = 0.0061 P = 0.0036
0.39 P = 0.011 NS NS
0.1 P = 0.0008 NS NS
-0.21 to -1.1 NS NS NS
Vmax P = 0.0065 P = 0.0003 NS
NS = non significantJournal of Circadian Rhythms 2009, 7:14 http://www.jcircadianrhythms.com/content/7/1/14
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ings on the scotopic ERG thus obtained could be
attributable to the effect of melatonin on cone function-
ing.
The way melatonin impacts the cone response is unclear.
It has been suggested from the avian model that the pres-
ence of melatonin in the circulation could be interpreted
by the system as a "night signal" shifting the retina to
night vision [11]. But as mentioned earlier, a direct effect
on dopamine (especially in day time) must also be con-
sidered. Interestingly, a correlation has been found
between the dopamine metabolite homovanillic acid
(HVA) and the blue cone b-wave amplitude in humans
[30]. Among those cocaine-dependant patients, the lower
was the presence of HVA in cerebrospinal fluid, the lower
was the blue cone b-wave. This is consistent with another
study showing that dopamine blockers such as chlorpro-
mazine and fluphenazine can reduce significantly the
human ERG cone-dominated response [31].
A mechanism implicating horizontal cells and dopamine
could also explain the cone ERG maximal response
decrease. These interconnecting neurons help to integrate
and regulate the input from multiple photoreceptors. A
dopamine reduction due to the presence of melatonin
could increase horizontal cell coupling since it has been
shown that dopamine antagonists enhance this phenom-
enon in mudpuppy retina [32]. Knowing that horizontal
cells have an inhibitory effect on cones [33], it seems con-
ceivable that increasing horizontal cell coupling (through
dopamine inhibition) could provoke a decrease of cone
maximal response to light.
However, we cannot exclude the possibility of an altera-
tion of intracellular calcium level by melatonin since this
hormone seems to increase the intracellular dispersion of
this ion and decrease the gap junction communication
between cells. But since this phenomenon has been
observed in astrocytes of chick diencephalons, we cannot
conclude that melatonin could have the same effect on
retinal gap junctions [34].
Regarding the sum of OPs reduction, the origin of this
effect is difficult to explain as the exact origin of all OPs is
not elucidated yet [35]. In the present study, however, the
ratio between the sum of OPs and b-wave amplitude
remains similar before and after melatonin, suggesting
that OPs were not more affected than the b-wave itself.
From our study, we can only conclude that the b-wave and
OPs generators are equally affected by melatonin.
Whereas the influence of melatonin on the b-wave was
obvious in our study, the effect on the a-wave was not con-
sistent. Since data obtained on primate have shown that
the a-wave is generated mostly by photoreceptors [36],
this suggests that exogenous melatonin does not have a
profound effect on photoreceptors even though MT1
receptors have been found on human cone photorecep-
tors [37]. However, there is also the possibility of a type II
error considering small amplitude-to-noise ratio of a-
wave and our small subjects sample.
Although it would have been interesting to perform the
same experiment including rods ERG it is unlikely that we
would have observed any difference on rods response. In
fact, a preliminary melatonin study (oral administration)
performed by our group with beagle dogs did not show
any significant change on rods ERG with 80 mg of mela-
tonin whereas a substantial effect on cone response was
observed [38]. Moreover, we were interested in testing the
impact of melatonin during the daytime (when it is some-
times ingested to treat circadian disorders) that is when
day vision generated by cones is most significant.
Because melatonin appears to have a negative impact on
cone function, we can suspect that naturally increasing
melatonin in the evening may play a role in decreasing the
impact of the cone system (day vision) in order to better
promote the rod system (night vision) and by doing so,
ensuring that the most suitable visual function is
enhanced according to the time of the day.
Conclusion
In conclusion, the negative impact of melatonin on cone
response may serve to promote night vision. The impact
of melatonin on retinal function must be taken into con-
sideration when this compound is used without any
supervision in chronic self-medication. Further assess-
ment should be conducted in animal species in order to
evaluate a potential effect of chronic use of this com-
pound that is considered as a nutritional (diet) supple-
ment in the United States of America.
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